Nucleic Acids Research, 2001, Vol. 29, No. 7 1534-1538
© 2001 Oxford University Press
Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells
1Carcinogenesis Group and 2Experimental Radiation Oncology Group, Cancer Research Campaign, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK
The strand transferase RAD51 is a component of the homologous recombination repair pathway. To examine the contribution of RAD51 to the genotoxic effects of ionising radiation, we have used a novel ribozyme strategy. A reporter gene vector was constructed so that expression of an inserted synthetic double-stranded ribozyme-encoding oligonucleotide would be under the control of the cytomegalovirus immediate-early gene enhancer/promoter system. The prostate tumour cell line LNCaP was transfected with this vector or a control vector, and a neomycin resistance gene on the vector was used to create geneticin-resistant stable cell lines. Three stable cell lines were shown by western blot analysis to have significant down-regulation of RAD51 to 20–50% of the levels expressed in control cell lines. All three cell lines had a similar increased sensitivity to 
-irradiation by 70 and 40%, respectively, compared to normal and empty vector-transfected cells, corresponding to dose-modifying factors of 
2.0 and 1.5 in the mid-range of the dose-response curves. The amount of RAD51 protein in transfected cell lines was shown to strongly correlate with the 
parameter obtained from fitted survival curves. These results highlight the importance of RAD51 in cellular responses to radiation and are the first to indicate the potential use of RAD51-targeted ribozyme minigenes in tumour radiosensitisation.
* To whom correspondence should be addressed. Tel: +44 161 446 3183; Fax: +44 161 446 3109; Email: gmargison{at}picr.man.ac.uk Present addresses: A.Tighe, School of Biological Sciences, University of Manchester, 2.205 Stopford Building, Oxford Road, Manchester M13 9PT, UK S.D.Scott, Experimental Oncology Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Bolderson, D. J. Richard, B.-B. S. Zhou, and K. K. Khanna Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair Clin. Cancer Res., October 15, 2009; 15(20): 6314 - 6320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Hine, A. Seluanov, and V. Gorbunova Use of the Rad51 promoter for targeted anti-cancer therapy PNAS, December 30, 2008; 105(52): 20810 - 20815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nomme, Y. Takizawa, S. F. Martinez, A. Renodon-Corniere, F. Fleury, P. Weigel, K.-i. Yamamoto, H. Kurumizaka, and M. Takahashi Inhibition of filament formation of human Rad51 protein by a small peptide derived from the BRC-motif of the BRCA2 protein. Genes Cells, May 1, 2008; 13(5): 471 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ambrosini, S. L. Seelman, L.-X. Qin, and G. K. Schwartz The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates the Effects of Topoisomerase I Poisons by Suppressing Rad51 Expression in a p53-Dependent Manner Cancer Res., April 1, 2008; 68(7): 2312 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fan, T. S. Kumaravel, F. Jalali, P. Marrano, J. A. Squire, and R. G. Bristow Defective DNA Strand Break Repair after DNA Damage in Prostate Cancer Cells: Implications for Genetic Instability and Prostate Cancer Progression Cancer Res., December 1, 2004; 64(23): 8526 - 8533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Russell, K. Brady, W. E. Burgan, M. A. Cerra, K. A. Oswald, K. Camphausen, and P. J. Tofilon Gleevec-Mediated Inhibition of Rad51 Expression and Enhancement of Tumor Cell Radiosensitivity Cancer Res., November 1, 2003; 63(21): 7377 - 7383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Collis, M. J. Swartz, W. G. Nelson, and T. L. DeWeese Enhanced Radiation and Chemotherapy-mediated Cell Killing of Human Cancer Cells by Small Inhibitory RNA Silencing of DNA Repair Factors Cancer Res., April 1, 2003; 63(7): 1550 - 1554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Slupianek, G. Hoser, I. Majsterek, A. Bronisz, M. Malecki, J. Blasiak, R. Fishel, and T. Skorski Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G2/M Phase, and Protection from Apoptosis Mol. Cell. Biol., June 15, 2002; 22(12): 4189 - 4201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Collis, V. K. Sangar, A. Tighe, S. A. Roberts, N. W. Clarke, J. H. Hendry, and G. P. Margison Development of a novel rapid assay to assess the fidelity of DNA double-strand-break repair in human tumour cells Nucleic Acids Res., January 15, 2002; 30(2): e1 - e1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Kim, C. Allen, B. M. Wagener, Z. Shen, and J. A. Nickoloff Overexpression of human RAD51 and RAD52 reduces double-strand break-induced homologous recombination in mammalian cells Nucleic Acids Res., November 1, 2001; 29(21): 4352 - 4360. [Abstract] [Full Text] [PDF]
|
|